SYF1e2212a3de0c4dc6ad3557ea25ab4d7bRegistry ID: 2024-513960-24-00|RecruitingPhase 4
Loading search results
interventional
N/A
1 country
1
The primary objective of this study is to evaluate the effects of ozanimod in RRMS patients in limiting the progression of brain neurodegenerative phenomena over the course of 2 years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 29, 2024
Actual (reported)The primary endpoints of this study are to assess, in RRMS patients treated with ozanimod, the changes from baseline over 2 years of: • Global brain atrophy (i.e., percent brain volume change [PBVC]); • Regional GM volume; • Regional WM volume; • Thalamic volume; • Cortical volume.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
Massimo Filippi
First Submitted
May 29, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.